Piper Jaffray Discontinues Coverage On ISPH

Piper Jaffray is discontinuing its coverage on Inspire Pharmaceuticals ISPH as the company has been fully acquired by Merck & Co. MRK. Piper Jaffray most recently rated the stock at Neutral and held a $5 price target on the stock. Says Piper Jaffray, in the report, “Investors should no longer rely on our last published rating, price target, model, or estimates on Inspire, as they will not be updated following the discontinuation of coverage date.” ISPH shareholders received $5 in cash per share after the company's final close this past Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsHealth CareInspire PharmaceuticalsMerck & Co. Inc.PharmaceuticalsPiper Jaffray & Co.
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!